Wen Fury

US Patent:

20100042330, Feb 18, 2010

Filed:

Aug 4, 2009

Appl. No.:

12/535179

Inventors:

Karthikeyan Swaminathan - Santa Clara CA, US
Wen Fury - New York NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

G06F 17/18
G06F 19/00

US Classification:

702 19, 702181

Abstract:

Methods, software, and systems are provided for determining the probability of an overlap set of entities having an overlap size, where the overlap set is independently selected from two sets of non-identical entities. Applications of the invention to microarrays are provided. Probability distributions are provided for determining the probability that the size of an overlap gene set from two different microarrays occurs by chance. Microarray analysis for determining the size of a statistically significant overlap gene set given two different microarrays is described. Overlap set size probability determinations that account for the total number of genes in two different microarrays and not just the common genes are described.

US Patent:

20120323497, Dec 20, 2012

Filed:

Aug 27, 2012

Appl. No.:

13/595355

Inventors:

Karthikeyan Swaminathan - San Jose CA, US
Wen Fury - New York NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

G06F 17/18

US Classification:

702 19

Abstract:

Methods, software, and systems are provided for determining the probability of an overlap set of entities having an overlap size, where the overlap set is independently selected from two sets of non-identical entities. Applications of the invention to microarrays are provided. Probability distributions are provided for determining the probability that the size of an overlap gene set from two different microarrays occurs by chance. Microarray analysis for determining the size of a statistically significant overlap gene set given two different microarrays is described. Overlap set size probability determinations that account for the total number of genes in two different microarrays and not just the common genes are described.

US Patent:

20210403567, Dec 30, 2021

Filed:

May 25, 2021

Appl. No.:

17/329545

Inventors:

- Tarrytown NY, US
Israel Lowy - Dobbs Ferry NY, US
Melissa Divya Mathias - Brooklyn NY, US
Wen Fury - New York NY, US

International Classification:

C07K 16/28
A61K 45/06
A61P 35/04

Abstract:

The present disclosure provides methods for treating, reducing the severity of, or inhibiting the growth of a tumor or improving overall survival in a cervical cancer patient, wherein the method includes selecting a patient with cervical cancer in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof such as cemiplimab or a bioequivalent thereof). In certain embodiments, the patient has recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

US Patent:

20210142867, May 13, 2021

Filed:

Nov 6, 2020

Appl. No.:

17/091484

Inventors:

- Tarrytown NY, US
Yu Bai - Tarrytown NY, US
Wen Fury - Tarrytown NY, US
Gurinder Atwal - Tarrytown NY, US

International Classification:

G16B 30/00
G16B 5/00

Abstract:

This disclosure relates to methods for deconvolving bulk or spatial RNA-sequencing data, computer readable medium storing processor-executable instructions adapted to deconvolve bulk or spatial RNA-sequencing data, and systems for deconvolving bulk or spatial RNA-sequencing data to characterize cell type compositions.

US Patent:

20200299682, Sep 24, 2020

Filed:

Mar 17, 2020

Appl. No.:

16/821453

Inventors:

- Tarrytown NY, US
Matthew Koss - Mount Kisco NY, US
Wen Fury - New York NY, US
Brian Zambrowicz - Sleepy Hollow NY, US

International Classification:

C12N 15/10
C12N 15/113
C12N 9/22
C12N 5/073
C12N 5/071

Abstract:

Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.

US Patent:

20180258164, Sep 13, 2018

Filed:

May 21, 2018

Appl. No.:

15/985660

Inventors:

- Tarrytown NY, US
Jeanne Allinne - New York NY, US
Wen Fury - New York NY, US
Yu Bai - Scarsdale NY, US

International Classification:

C07K 16/24
A61K 39/395
A61K 45/06
A61K 38/17
C07K 14/575
G01N 33/68
A61K 39/00

Abstract:

The present invention relates to the identification of certain biomarkers for use in identifying patients who have, or are likely to develop an IL-33 mediated disease or disorder and who are more likely to respond to therapy with an IL-33 antagonist. The invention also relates to methods of treatment of an IL-33-mediated disease or disorder in a patient by administering an IL-33 antagonist to the patient in need thereof and monitoring the effectiveness of therapy using the biomarkers described herein. Also provided are methods for decreasing the level of at least one biomarker in a subject suffering from an IL-33-mediated disease or disorder, and methods for treating such diseases or disorders according to the expression levels of one or more biomarkers. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-33 antagonist.

US Patent:

20170308642, Oct 26, 2017

Filed:

Jul 12, 2017

Appl. No.:

15/648164

Inventors:

- Tarrytown NY, US
Wen Fury - New York NY, US

International Classification:

G06F 19/20
G06F 19/24

Abstract:

Methods, software, and systems are provided for determining the probability of an overlap set of entities having an overlap size, where the overlap set is independently selected from two sets of non-identical entities. Applications of the invention to microarrays are provided. Probability distributions are provided for determining the probability that the size of an overlap gene set from two different microarrays occurs by chance. Microarray analysis for determining the size of a statistically significant overlap gene set given two different microarrays is described. Overlap set size probability determinations that account for the total number of genes in two different microarrays and not just the common genes are described.

US Patent:

20170096483, Apr 6, 2017

Filed:

Oct 5, 2016

Appl. No.:

15/285772

Inventors:

- Tarrytown NY, US
Jeanne Allinne - New York NY, US
Wen Fury - New York NY, US
Yu Bai - Scarsdale NY, US

International Classification:

C07K 16/24
A61K 38/17
A61K 45/06
C07K 14/715
G01N 33/68
A61K 39/395

Abstract:

The present invention relates to the identification of certain biomarkers for use in identifying patients who have, or are likely to develop an IL-33 mediated disease or disorder and who are more likely to respond to therapy with an IL-33 antagonist. The invention also relates to methods of treatment of an IL-33-mediated disease or disorder in a patient by administering an IL-33 antagonist to the patient in need thereof and monitoring the effectiveness of therapy using the biomarkers described herein. Also provided are methods for decreasing the level of at least one biomarker in a subject suffering from an IL-33-mediated disease or disorder, and methods for treating such diseases or disorders according to the expression levels of one or more biomarkers. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-33 antagonist.